Viviana Wilches, HBSc, MBiotech

Clinical Development Manager
GlaxoSmithKline

Disclosure: GlaxoSmithKline (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 116 - Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

  Oral Abstract